American International Group, Inc. Annexon, Inc. Transaction History

American International Group, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$4.03 - $7.81 $42,355 - $82,083	10,510 Added 46.33%	33,197 $238,000
Q4 2023 Feb 13, 2024	SELL	$1.63 - $4.63 $148 - $421	-91 Reduced 0.4%	22,687 $102,000
Q3 2023 Nov 13, 2023	BUY	$2.13 - $3.84 $1,725 - $3,110	810 Added 3.69%	22,778 $53,000
Q2 2023 Aug 04, 2023	BUY	$2.1 - $6.37 $46,132 - $139,936	21,968 New	21,968 $77,000
Q2 2022 Aug 12, 2022	SELL	$2.11 - $4.06 $32,662 - $62,848	-15,480 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.73 - $11.94 $2,975 - $13,014	-1,090 Reduced 6.58%	15,480 $42,000
Q4 2021 Feb 11, 2022	SELL	$11.49 - $22.0 $5,699 - $10,912	-496 Reduced 2.91%	16,570 $190,000
Q3 2021 Nov 12, 2021	SELL	$16.35 - $23.4 $6,621 - $9,477	-405 Reduced 2.32%	17,066 $318,000
Q2 2021 Aug 13, 2021	BUY	$17.81 - $27.48 $34,337 - $52,981	1,928 Added 12.4%	17,471 $393,000
Q1 2021 May 07, 2021	BUY	$22.0 - $35.01 $142,208 - $226,304	6,464 Added 71.2%	15,543 $433,000
Q4 2020 Feb 12, 2021	BUY	$20.81 - $30.55 $5,473 - $8,034	263 Added 2.98%	9,079 $227,000
Q3 2020 Nov 04, 2020	BUY	$17.5 - $30.23 $154,280 - $266,507	8,816 New	8,816 $267,000

146

102M

178K

159K

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $249M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.